Page last updated: 2024-10-17

lactic acid and Hemolysis

lactic acid has been researched along with Hemolysis in 84 studies

Lactic Acid: A normal intermediate in the fermentation (oxidation, metabolism) of sugar. The concentrated form is used internally to prevent gastrointestinal fermentation. (From Stedman, 26th ed)
2-hydroxypropanoic acid : A 2-hydroxy monocarboxylic acid that is propanoic acid in which one of the alpha-hydrogens is replaced by a hydroxy group.

Hemolysis: The destruction of ERYTHROCYTES by many different causal agents such as antibodies, bacteria, chemicals, temperature, and changes in tonicity.

Research Excerpts

ExcerptRelevanceReference
" BJ rats showed markedly reduced glomerular filtration rate (GFR, inulin clearance) associated with intense renal vasoconstriction, hemolysis, hemoglobinuria, reduced glutathione and increased systemic and renal markers of nitro-oxidative stress (Nitrotyrosine)."7.85Allopurinol attenuates acute kidney injury following Bothrops jararaca envenomation. ( Canale, D; Crajoinas, R; Ferreira, D; Girardi, ACC; Gois, PHF; Malaque, C; Martines, MS; Massola Shimizu, MH; Seguro, AC; Volpini, R, 2017)
"The experiments test if experimental PE causes red blood cell hemolysis, arginase release and depletion of l-arginine and determine if arginase inhibition preserves l-arginine and improves pulmonary hemodynamics during PE."7.78Arginase depletes plasma l-arginine and decreases pulmonary vascular reserve during experimental pulmonary embolism. ( Das, SK; Fulkerson, MB; Gellar, MA; Kline, JA; Watts, JA, 2012)
" The hemolysis index, lactate and potassium concentrations, prothrombin time (PT), activated partial thromboplastin time (aPTT), and fibrinogen were measured on plasma aliquots."3.88In vitro assessment of quality of citrate-phosphate-dextrose-adenine-1 preserved feline blood collected by a commercial closed system. ( Bozzato, E; Capello, K; Carminato, A; Corrò, M; Crestani, C; Cro, A; Mutinelli, F; Stefani, A; Vascellari, M, 2018)
" BJ rats showed markedly reduced glomerular filtration rate (GFR, inulin clearance) associated with intense renal vasoconstriction, hemolysis, hemoglobinuria, reduced glutathione and increased systemic and renal markers of nitro-oxidative stress (Nitrotyrosine)."3.85Allopurinol attenuates acute kidney injury following Bothrops jararaca envenomation. ( Canale, D; Crajoinas, R; Ferreira, D; Girardi, ACC; Gois, PHF; Malaque, C; Martines, MS; Massola Shimizu, MH; Seguro, AC; Volpini, R, 2017)
"The experiments test if experimental PE causes red blood cell hemolysis, arginase release and depletion of l-arginine and determine if arginase inhibition preserves l-arginine and improves pulmonary hemodynamics during PE."3.78Arginase depletes plasma l-arginine and decreases pulmonary vascular reserve during experimental pulmonary embolism. ( Das, SK; Fulkerson, MB; Gellar, MA; Kline, JA; Watts, JA, 2012)
"Melatonin is an endogen substance with several physiological functions, acting as an important antioxidant."1.48PLGA Nanoparticles and Polysorbate-80-Coated PLGA Nanoparticles Increase the In vitro Antioxidant Activity of Melatonin. ( Khalil, NM; Mainardes, RM; Martins, LG, 2018)
" Thus, there is a need to develop a formulation which can eliminate the need of frequent dosing and enhance patient's acquiescence."1.48Hepatitis B Antigen Loaded Biodegradable Polymeric Nanoparticles: Formulation Optimization and In-vivo Immunization in BALB/c Mice. ( Dewangan, HK; Maurya, L; Singh, S; Srivastava, A, 2018)
" There is currently an unmet need for an efficacious (AMB) formulation amenable to oral administration with better bioavailability and lower nephrotoxicity."1.46Oral administration of amphotericin B nanoparticles: antifungal activity, bioavailability and toxicity in rats. ( AlQuadeib, BT; Horrocks, B; Radwan, MA; Šiller, L; Wright, MC, 2017)
"The development of antibacterial drugs to overcome various pathogenic species, which inhabit the oral cavity, faces several challenges, such as salivary flow and enzymatic activity that restrict dosage retention."1.43Sustained Release of Antibacterial Lipopeptides from Biodegradable Polymers against Oral Pathogens. ( Bachrach, G; Beyth, N; Beyth, S; Domb, AJ; Eckhard, LH; Houri-Haddad, Y; Shai, Y; Sol, A; Zeharia, R, 2016)
"Hemolysis is common in all extracorporeal circuits as evident by the elevated plasma free hemoglobin (PFHb) level."1.42Plasma Free Hemoglobin Is an Independent Predictor of Mortality among Patients on Extracorporeal Membrane Oxygenation Support. ( Caldeira, C; Camporesi, EM; Mangar, D; Mirsaeidi, M; Omar, HR; Socias, S; Sprenker, C, 2015)
"Mitomycin C (MMC) is a water-soluble anticancer drug extensively used in first-line chemotherapy but is limited by its poor aqueous stability in vitro, rapid elimination from the body, and lack of target specificity."1.40Mitomycin C-soybean phosphatidylcholine complex-loaded self-assembled PEG-lipid-PLA hybrid nanoparticles for targeted drug delivery and dual-controlled drug release. ( Hou, Z; Huang, Y; Jia, M; Li, Y; Lin, J; Wu, H; Wu, S; Yang, X, 2014)
"Amphotericin B (AmB) is a broad spectrum antifungal and antileishmenial agent and its clinical use is limited due to substantial dose limiting toxicities such as nephrotoxicity."1.36Development of amphotericin B loaded polymersomes based on (PEG)(3)-PLA co-polymers: Factors affecting size and in vitro evaluation. ( Jain, JP; Kumar, N, 2010)
"3%) and severe nephrotoxicity, was entrapped into poly(lactide-co-glycolide) (PLGA) nanoparticles to improve the oral bioavailability and to minimize the adverse effects associated with it."1.35Biodegradable nanoparticles improve oral bioavailability of amphotericin B and show reduced nephrotoxicity compared to intravenous Fungizone. ( Italia, JL; Ravi Kumar, MN; Singh, D; Yahya, MM, 2009)
" The pharmacokinetic profiles of ITZ-PM for itraconazole and its major metabolite, hydroxy-itraconazole, were comparable to those of the cyclodextrin formulations (Sporanox(R) Injection and Oral Solution) in rats and dogs."1.34A mixed polymeric micellar formulation of itraconazole: Characteristics, toxicity and pharmacokinetics. ( Hwang, SJ; Kim, BO; Kim, SO; Seo, MH; Shim, M; Yi, Y; Yoon, HJ, 2007)
"The lactic acid was injected to rabbit through the auricular vein till the final concentration for the circulating blood was 0."1.30Effect of lactic acid on water content and osmotic fragility of erythrocytes in vivo. ( Higuchi, T; Kageyama, K; Kogawa, H; Mitsudo, M; Satoh, M, 1997)

Research

Studies (84)

TimeframeStudies, this research(%)All Research%
pre-19905 (5.95)18.7374
1990's8 (9.52)18.2507
2000's14 (16.67)29.6817
2010's56 (66.67)24.3611
2020's1 (1.19)2.80

Authors

AuthorsStudies
Vardaki, MZ1
Schulze, HG1
Serrano, K2
Blades, MW1
Devine, DV2
Turner, RFB1
Sahu, P1
Kashaw, SK1
Jain, S2
Sau, S1
Iyer, AK1
Bardyn, M1
Rappaz, B1
Jaferzadeh, K1
Crettaz, D1
Tissot, JD1
Moon, I1
Turcatti, G1
Lion, N1
Prudent, M1
Martins, LG1
Khalil, NM1
Mainardes, RM1
Gois, PHF1
Martines, MS1
Ferreira, D1
Volpini, R1
Canale, D1
Malaque, C1
Crajoinas, R1
Girardi, ACC1
Massola Shimizu, MH1
Seguro, AC1
Crestani, C1
Stefani, A1
Carminato, A1
Cro, A1
Capello, K1
Corrò, M1
Bozzato, E1
Mutinelli, F1
Vascellari, M1
Dewangan, HK1
Singh, S1
Maurya, L1
Srivastava, A1
Proffitt, S1
Curnow, E1
Brown, C1
Bashir, S1
Cardigan, R2
Larsson, L2
Larsson, S1
Derving, J1
Watz, E1
Uhlin, M1
Qiao, H1
Li, J2
Wang, Y2
Ping, Q1
Wang, G1
Gu, X1
Arunraj, TR1
Sanoj Rejinold, N1
Ashwin Kumar, N1
Jayakumar, R1
Gupta, M1
Chashoo, G1
Sharma, PR1
Saxena, AK1
Gupta, PN2
Agrawal, GP2
Vyas, SP1
Winter, KM1
Johnson, L1
Kwok, M1
Vidovic, D1
Hyland, RA1
Mufti, N1
Erickson, A1
Marks, DC1
Lv, L1
Shen, Y2
Li, M2
Xu, X2
Guo, S1
Huang, S1
He, Z1
Wang, Q2
Sun, Y1
Shen, M1
Zhu, M1
Gu, M1
Duan, Y1
Sathler, PC1
Lourenço, AL1
Rodrigues, CR1
da Silva, LC1
Cabral, LM1
Jordão, AK1
Cunha, AC1
Vieira, MC1
Ferreira, VF1
Carvalho-Pinto, CE1
Kang, HC1
Castro, HC1
Mercado-Pagán, ÁE1
Ker, DF1
Yang, Y1
Nehate, C1
Alam, N1
Khare, V1
Dubey, RD1
Saneja, A1
Kour, S1
Singh, SK1
Liu, L1
Li, N1
Lei, T1
Li, K1
Zhang, Y1
Li, L1
Li, H2
Yuan, M2
Gaspar, VM1
Gonçalves, C1
de Melo-Diogo, D1
Costa, EC1
Queiroz, JA1
Pichon, C1
Sousa, F1
Correia, IJ1
Yang, C1
Chen, H1
Zhao, J1
Pang, X1
Xi, Y1
Zhai, G1
Li, Y3
Wu, H1
Yang, X1
Jia, M1
Huang, Y1
Lin, J1
Wu, S1
Hou, Z1
Wei, Z1
Tian, P1
Liu, X1
Zhou, B1
Fornaguera, C2
Grijalvo, S1
Galán, M1
Fuentes-Paniagua, E1
de la Mata, FJ1
Gómez, R1
Eritja, R1
Calderó, G2
Solans, C2
Szymonowicz, M1
Rybak, Z1
Witkiewicz, W1
Pezowicz, C1
Filipiak, J1
Mitjans, M1
Vinardell, MP1
Vauthier, C1
Omar, HR1
Mirsaeidi, M1
Socias, S1
Sprenker, C1
Caldeira, C1
Camporesi, EM1
Mangar, D1
Pillai, GJ1
Greeshma, MM1
Menon, D1
Levin, E1
Chen, D2
Hansen, A1
Turner, TR1
Kurach, J1
Reidel, A1
Boecker, WF1
Acker, JP1
Brisbois, EJ1
Major, TC1
Goudie, MJ1
Meyerhoff, ME1
Bartlett, RH1
Handa, H1
Eckhard, LH1
Houri-Haddad, Y1
Sol, A1
Zeharia, R1
Shai, Y1
Beyth, S1
Domb, AJ1
Bachrach, G1
Beyth, N1
Mambrini, G1
Mandolini, M1
Rossi, L1
Pierigè, F1
Capogrossi, G1
Salvati, P1
Serafini, S1
Benatti, L1
Magnani, M1
Gulliksson, H1
Meinke, S1
Ravizza, A1
Höglund, P1
Bontekoe, IJ1
van der Meer, PF1
de Korte, D1
Radwan, MA1
AlQuadeib, BT1
Šiller, L1
Wright, MC1
Horrocks, B1
Cruz, J1
Flórez, J1
Torres, R1
Urquiza, M1
Gutiérrez, JA1
Guzmán, F1
Ortiz, CC1
Nguyen, J1
Steele, TW1
Merkel, O1
Reul, R1
Kissel, T1
Bang, JY1
Song, CE1
Kim, C1
Park, WD1
Cho, KR1
Kim, PI1
Lee, SR1
Chung, WT1
Choi, KC1
Italia, JL1
Yahya, MM1
Singh, D1
Ravi Kumar, MN1
Hu, W1
Huang, ZM1
Meng, SY1
He, CL1
Makley, AT1
Goodman, MD1
Friend, LA1
Johannigman, JA1
Dorlac, WC1
Lentsch, AB1
Pritts, TA1
Jain, JP1
Kumar, N1
Lu, P1
Cao, L1
Liu, Y1
Wu, X1
Zhou, Q1
Zhang, Z1
Chen, T1
Guo, X1
Zhou, S1
Sullivan, R1
Santarpia, P1
Lavender, S1
Gittins, E1
Liu, Z1
Anderson, MH1
He, J1
Shi, W1
Eckert, R1
Thasneem, YM1
Sajeesh, S1
Sharma, CP1
Watts, JA1
Gellar, MA1
Fulkerson, MB1
Das, SK1
Kline, JA1
Yallapu, MM1
Ebeling, MC1
Chauhan, N1
Jaggi, M1
Chauhan, SC1
Gupta, S1
Agarwal, A1
Gupta, NK1
Saraogi, G1
Agrawal, H1
Surolia, R1
Pachauri, M1
Ghosh, PC1
Kong, M1
Cheng, XJ1
Dang, QF1
Zhou, X1
Wei, YN1
Chen, XG1
Xu, H1
Nguyen, KT1
Brilakis, ES1
Yang, J1
Fuh, E1
Banerjee, S1
Van de Ven, H1
Paulussen, C1
Feijens, PB1
Matheeussen, A1
Rombaut, P1
Kayaert, P1
Van den Mooter, G1
Weyenberg, W1
Cos, P1
Maes, L1
Ludwig, A1
Zelenak, C1
Pasham, V1
Jilani, K1
Tripodi, PM1
Rosaclerio, L1
Pathare, G1
Lupescu, A1
Faggio, C1
Qadri, SM1
Lang, F1
Xiong, Y1
Jiang, W1
Sun, C1
Ouahab, A1
Tu, J1
Essa, S1
Louhichi, F1
Raymond, M1
Hildgen, P1
Yang, F1
Chen, W1
Liu, J1
Huang, W1
Jin, M1
Gao, Z1
Thomas, S1
Hancock, V1
Ciborowski, M1
Lipska, A1
Godzien, J1
Ferrarini, A1
Korsak, J1
Radziwon, P1
Tomasiak, M1
Barbas, C1
Birri, DJ1
Brede, DA1
Tessema, GT1
Nes, IF1
Burda, G1
Trittenwein, H1
Carole, H1
Trittenwein, G1
Carlson, GA1
Dragoo, JL1
Samimi, B1
Bruckner, DA1
Bernard, GW1
Hedrick, M1
Benhaim, P1
Kim, D1
El-Shall, H1
Dennis, D1
Morey, T1
Yi, Y1
Yoon, HJ1
Kim, BO1
Shim, M1
Kim, SO1
Hwang, SJ1
Seo, MH1
Picker, SM1
Radojska, SM1
Gathof, BS1
Niinistö, K1
Raekallio, M1
Sankari, S1
Qiao, M1
Hao, T1
Zhao, X1
Hu, H1
Ma, X1
Cenni, E1
Granchi, D1
Avnet, S1
Fotia, C1
Salerno, M1
Micieli, D1
Sarpietro, MG1
Pignatello, R1
Castelli, F1
Baldini, N1
Riede, U1
Sandritter, W1
Mittermayer, C1
Jausel-Hüsken, S1
Deuticke, B1
Heaton, WA1
Holme, S1
Smith, K1
Brecher, ME1
Pineda, A1
AuBuchon, JP2
Nelson, E1
Högman, CF2
Eriksson, L2
Gong, J1
Högman, AB1
Vikholm, K1
Debrauwere, J1
Payrat, JM1
Stewart, M1
Kogawa, H1
Satoh, M1
Mitsudo, M1
Higuchi, T1
Kageyama, K1
Thin, AG1
Hamzah, Z1
FitzGerald, MX1
McLoughlin, P1
Freaney, R1
Ecker, T1
Hitzler, WE1
Pickard, CA1
Herschel, LH1
Roger, JC1
Tracy, JE1
Purmal, A1
Chapman, J1
Ackerman, S1
Beach, KJ1
Goto, I1
Shimizu, T1
Maede, Y1
Foxdal, P1
Bergqvist, Y1
Eckerbom, S1
Sandhagen, B1
Ericson, A1
Reppucci, AJ1
Corbucci, GG1
Angué, M1
Chatelain, P1
Fiabane, S1
Domy, M1
Guignier, F1
Richaud, P1
Petrenko, IuM1
Vladimirov, IuA1
Stephan, H1
Larsen, R1
Sonntag, H1

Clinical Trials (1)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
A Feasibility Study to Consider the Relationship Between Markers of Red Cell Damage, Inflammation and the Recovery Process of Newborns Requiring Extracorporeal Membrane Oxygenation (ECMO) for Persistent Pulmonary Hypertension of the Newborn (PPHN): Mi-ECM[NCT02940327]24 participants (Actual)Observational2016-02-19Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Allogenic Red Cell Transfusion Volume

Clinical and biochemical markers of organ failure (NCT02940327)
Timeframe: 24 hours after ECMO is discontinued

Interventionml (Mean)
7+ Days289.6
<7 Days479.2

CD14/41

Change of markers of platelet and leukocyte activation in arterial blood and analysed by flow cytometry. (NCT02940327)
Timeframe: 12 hours after ECMO commencement

Interventionpercentage change (Mean)
7+ Days1.5
<7 Days0.84

CD14/41

Change of markers of platelet and leukocyte activation in arterial blood and analysed by flow cytometry. (NCT02940327)
Timeframe: 24 hours after ECMO commencement

Interventionpercentage change (Mean)
7+ Days3.02
<7 Days0.38

CD14/41

Change of markers of platelet and leukocyte activation in arterial blood and analysed by flow cytometry. (NCT02940327)
Timeframe: 24 hours after ECMO decannulation

Interventionpercentage change (Mean)
7+ Days1.01
<7 Days0.40

CD14/41

Change of markers of platelet and leukocyte activation in arterial blood and analysed by flow cytometry. (NCT02940327)
Timeframe: 48 hours after ECMO commencement

Interventionpercentage change (Mean)
7+ Days0.29
<7 Days0.27

CD14/41

Change of markers of platelet and leukocyte activation in arterial blood and analysed by flow cytometry. (NCT02940327)
Timeframe: 72 hours after ECMO commencement

Interventionpercentage change (Mean)
7+ Days0.72
<7 Days0.59

CD16/41

Change of markers of platelet and leukocyte activation in arterial blood and analysed by flow cytometry. (NCT02940327)
Timeframe: 12 hours after ECMO commencement

Interventionpercent change (Mean)
7+ Days1.90
<7 Days1.13

CD16/41

Change of markers of platelet and leukocyte activation in arterial blood and analysed by flow cytometry. (NCT02940327)
Timeframe: 24 hours after decannulation

Interventionpercentage change (Mean)
7+ Days1.56
<7 Days0.6

CD16/41

Change of markers of platelet and leukocyte activation in arterial blood and analysed by flow cytometry. (NCT02940327)
Timeframe: 24 hours after ECMO commencement

Interventionpercentage change (Mean)
7+ Days3.11
<7 Days0.64

CD16/41

Change of markers of platelet and leukocyte activation in arterial blood and analysed by flow cytometry. (NCT02940327)
Timeframe: 48 hours after ECMO commencement

Interventionpercentage change (Mean)
7+ Days0.73
<7 Days0.4

CD16/41

Change of markers of platelet and leukocyte activation in arterial blood and analysed by flow cytometry. (NCT02940327)
Timeframe: 72 hours after ECMO commencement

Interventionpercentage change (Mean)
7+ Days1.55
<7 Days0.93

CD64/163

Change of markers of platelet and leukocyte activation in arterial blood and analysed by flow cytometry. (NCT02940327)
Timeframe: 12 hours after ECMO commencement

Interventionpercentage change (Mean)
7+ Days8.7
<7 Days4.65

CD64/163

Change of markers of platelet and leukocyte activation in arterial blood and analysed by flow cytometry. (NCT02940327)
Timeframe: 24 hours after decannulation

Interventionpercentage change (Mean)
7+ Days3.2
<7 Days2.27

CD64/163

Change of markers of platelet and leukocyte activation in arterial blood and analysed by flow cytometry. (NCT02940327)
Timeframe: 24 hours after ECMO commencement

Interventionpercentage change (Mean)
7+ Days7.34
<7 Days1.89

CD64/163

Change of markers of platelet and leukocyte activation in arterial blood and analysed by flow cytometry. (NCT02940327)
Timeframe: 48 hours after ECMO commencement

Interventionpercentage change (Mean)
7+ Days3.26
<7 Days0.92

CD64/163

Change of markers of platelet and leukocyte activation in arterial blood and analysed by flow cytometry. (NCT02940327)
Timeframe: 72 hours after ECMO commencement

Interventionpercentage change (Mean)
7+ Days3.31
<7 Days1.9

Change of Serum Haemoglobin Levels

Clinical and biochemical markers of organ failure (NCT02940327)
Timeframe: 12 hours after ECMO commencement

Interventiong/L (Mean)
7+ Days109.64
<7 Days112.07

Change of Serum Haemoglobin Levels

Clinical and biochemical markers of organ failure (NCT02940327)
Timeframe: 24 hours after decannulation

Interventiong/L (Mean)
7+ Days109.25
<7 Days110.23

Change of Serum Haemoglobin Levels

Clinical and biochemical markers of organ failure (NCT02940327)
Timeframe: 24 hours after ECMO commencement

Interventiong/L (Mean)
7+ Days114.30
<7 Days109.43

Change of Serum Haemoglobin Levels

Clinical and biochemical markers of organ failure (NCT02940327)
Timeframe: 48 hours after ECMO commencement

Interventiong/L (Mean)
7+ Days112.56
<7 Days113.08

Change of Serum Haemoglobin Levels

Clinical and biochemical markers of organ failure (NCT02940327)
Timeframe: 72 hours after ECMO commencement

Interventiong/L (Mean)
7+ Days112.90
<7 Days109.89

Change of Serum Haemoglobin Levels

Clinical and biochemical markers of organ failure (NCT02940327)
Timeframe: baseline

Interventiong/L (Mean)
7+ Days151.5
<7 Days145.4

Duration on ECMO

Clinical and biochemical markers of organ failure (NCT02940327)
Timeframe: > 7 days or did not survive to discharge

Interventionhours (Median)
7+ Days292
<7 Days80

Heart Injury as Determined by Serum Troponin Levels

Clinical and biochemical markers of organ failure (NCT02940327)
Timeframe: 12 hours after ECMO commencement

Interventionng/ml (Mean)
7+ Days7.89
<7 Days6.96

Heart Injury as Determined by Serum Troponin Levels

Clinical and biochemical markers of organ failure (NCT02940327)
Timeframe: 24 hours after decannulation

Interventionng/ml (Mean)
7+ Days9.54
<7 Days7.44

Heart Injury as Determined by Serum Troponin Levels

Clinical and biochemical markers of organ failure (NCT02940327)
Timeframe: 24 hours after ECMO commencement

Interventionng/ml (Mean)
7+ Days3.71
<7 Days3.11

Heart Injury as Determined by Serum Troponin Levels

Clinical and biochemical markers of organ failure (NCT02940327)
Timeframe: 48 hours after ECMO commencement

Interventionng/ml (Mean)
7+ Days2.13
<7 Days1.81

Heart Injury as Determined by Serum Troponin Levels

Clinical and biochemical markers of organ failure (NCT02940327)
Timeframe: 72 hours after ECMO commencement

Interventionng/ml (Mean)
7+ Days5.51
<7 Days5.88

Number of Participants Requiring Non Red Cell Transfusion

Clinical and biochemical markers of organ failure (NCT02940327)
Timeframe: 24 hours after ECMO is discontinued

InterventionParticipants (Count of Participants)
7+ Days10
<7 Days10

Number of Participants With Acute Kidney Injury

Clinical and biochemical markers of organ failure (NCT02940327)
Timeframe: >7 days or did not survive to discharge

Interventionparticipants (Number)
7+ Days3
<7 Days0

Reviews

1 review available for lactic acid and Hemolysis

ArticleYear
Circulatory shock: a review.
    Pathology, 1981, Volume: 13, Issue:2

    Topics: Adenosine Triphosphate; Blood Coagulation; Blood Pressure; Cardiac Output; Glycolysis; Hemolysis; Hu

1981

Trials

3 trials available for lactic acid and Hemolysis

ArticleYear
Lactate determination in exercise testing using an electrochemical analyser: with or without blood lysis?
    European journal of applied physiology and occupational physiology, 1999, Volume: 79, Issue:2

    Topics: Adult; Electrochemistry; Exercise Test; Hemolysis; Humans; Lactic Acid; Male; Oxygen Consumption

1999
Production of pathogen-inactivated RBC concentrates using PEN110 chemistry: a Phase I clinical study.
    Transfusion, 2002, Volume: 42, Issue:2

    Topics: 2,3-Diphosphoglycerate; ABO Blood-Group System; Adenosine Triphosphate; Adult; Blood Donors; Blood G

2002
The role of reduced glutathione during the course of acute haemolysis in glucose-6-phosphate dehydrogenase deficient patients: clinical and pharmacodynamic aspects.
    International journal of clinical pharmacology research, 1990, Volume: 10, Issue:5

    Topics: Adolescent; Adult; Alanine Transaminase; Aspartate Aminotransferases; Cell Hypoxia; Double-Blind Met

1990

Other Studies

80 other studies available for lactic acid and Hemolysis

ArticleYear
Non-invasive monitoring of red blood cells during cold storage using handheld Raman spectroscopy.
    Transfusion, 2021, Volume: 61, Issue:7

    Topics: Adult; Blood Glucose; Blood Preservation; Blood Safety; Cold Temperature; Erythrocytes; Feasibility

2021
Assessment of penetration potential of pH responsive double walled biodegradable nanogels coated with eucalyptus oil for the controlled delivery of 5-fluorouracil: In vitro and ex vivo studies.
    Journal of controlled release : official journal of the Controlled Release Society, 2017, 05-10, Volume: 253

    Topics: Animals; Antimetabolites, Antineoplastic; Apoptosis; Cell Line; Cell Survival; Chitosan; Delayed-Act

2017
Red blood cells ageing markers: a multi-parametric analysis.
    Blood transfusion = Trasfusione del sangue, 2017, Volume: 15, Issue:3

    Topics: Blood Preservation; Cell-Derived Microparticles; Citrates; Erythrocyte Aging; Erythrocytes; Glucose;

2017
PLGA Nanoparticles and Polysorbate-80-Coated PLGA Nanoparticles Increase the In vitro Antioxidant Activity of Melatonin.
    Current drug delivery, 2018, Volume: 15, Issue:4

    Topics: Antioxidants; Drug Liberation; Hemolysis; In Vitro Techniques; Lactic Acid; Melatonin; Nanoparticles

2018
Allopurinol attenuates acute kidney injury following Bothrops jararaca envenomation.
    PLoS neglected tropical diseases, 2017, Volume: 11, Issue:11

    Topics: Acute Kidney Injury; Allopurinol; Animals; Antioxidants; Bothrops; Crotalid Venoms; Glomerular Filtr

2017
In vitro assessment of quality of citrate-phosphate-dextrose-adenine-1 preserved feline blood collected by a commercial closed system.
    Journal of veterinary internal medicine, 2018, Volume: 32, Issue:3

    Topics: 2,3-Diphosphoglycerate; Adenosine Triphosphate; Animals; Blood Cell Count; Blood Preservation; Blood

2018
Hepatitis B Antigen Loaded Biodegradable Polymeric Nanoparticles: Formulation Optimization and In-vivo Immunization in BALB/c Mice.
    Current drug delivery, 2018, Volume: 15, Issue:8

    Topics: Adjuvants, Immunologic; Alum Compounds; Animals; Cell Proliferation; Drug Compounding; Drug Liberati

2018
Comparison of automated and manual methods for washing red blood cells.
    Transfusion, 2018, Volume: 58, Issue:9

    Topics: Adenine; Automation; Blood Glucose; Blood Preservation; Erythrocyte Transfusion; Erythrocyte Volume;

2018
A novel protocol for cryopreservation of paediatric red blood cell units allows increased availability of rare blood types.
    Vox sanguinis, 2019, Volume: 114, Issue:7

    Topics: Blood Group Antigens; Blood Preservation; Child; Cryopreservation; Erythrocytes; Freezing; Glucose;

2019
Synthesis and characterization of multi-functional linear-dendritic block copolymer for intracellular delivery of antitumor drugs.
    International journal of pharmaceutics, 2013, Aug-16, Volume: 452, Issue:1-2

    Topics: Animals; Antineoplastic Agents; Cell Survival; Cells, Cultured; Dendrimers; Docetaxel; Drug Delivery

2013
Bio-responsive chitin-poly(L-lactic acid) composite nanogels for liver cancer.
    Colloids and surfaces. B, Biointerfaces, 2014, Jan-01, Volume: 113

    Topics: Cell Survival; Chitin; Doxorubicin; Hemolysis; Hep G2 Cells; Humans; Lactic Acid; Liver Neoplasms; N

2014
Dual targeted polymeric nanoparticles based on tumor endothelium and tumor cells for enhanced antitumor drug delivery.
    Molecular pharmaceutics, 2014, Mar-03, Volume: 11, Issue:3

    Topics: Animals; Antineoplastic Agents; Apoptosis; CD13 Antigens; Cell Cycle; Cell Proliferation; Cells, Cul

2014
Red blood cell in vitro quality and function is maintained after S-303 pathogen inactivation treatment.
    Transfusion, 2014, Volume: 54, Issue:7

    Topics: 2,3-Diphosphoglycerate; Acridines; Adenosine Triphosphate; Alkylating Agents; Blood Preservation; Bl

2014
Preparation and in vitro evaluation of novel poly(anhydride-ester)-based amphiphilic copolymer curcumin-loaded micelles.
    Journal of biomedical nanotechnology, 2014, Volume: 10, Issue:2

    Topics: Animals; Cell Cycle; Cell Death; Curcumin; Endocytosis; Esters; HeLa Cells; Hemolysis; Humans; Hydro

2014
The biocompatibility evaluation of mPEG-PLGA-PLL copolymer and different LA/GA ratio effects for biocompatibility.
    Journal of biomaterials science. Polymer edition, 2014, Volume: 25, Issue:9

    Topics: Adsorption; Animals; Blood Coagulation Tests; Cell Line; Complement System Proteins; Dose-Response R

2014
In vitro and in vivo analysis of the antithrombotic and toxicological profile of new antiplatelets N-acylhydrazone derivatives and development of nanosystems: determination of novel NAH derivatives antiplatelet and nanotechnological approach.
    Thrombosis research, 2014, Volume: 134, Issue:2

    Topics: Adult; Animals; Blood Coagulation; Chlorocebus aethiops; Drug Carriers; Hemolysis; Humans; Hydrazine

2014
Hemocompatibility evaluation of small elastomeric hollow fiber membranes as vascular substitutes.
    Journal of biomaterials applications, 2014, Volume: 29, Issue:4

    Topics: Adsorption; Biocompatible Materials; Blood Proteins; Blood Vessel Prosthesis; Elastomers; Hemolysis;

2014
Development and evaluation of paclitaxel loaded PLGA:poloxamer blend nanoparticles for cancer chemotherapy.
    International journal of biological macromolecules, 2014, Volume: 69

    Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Drug Carriers; Drug Discovery; Drug Stability; Hem

2014
The in vitro biological properties of Mg-Zn-Sr alloy and superiority for preparation of biodegradable intestinal anastomosis rings.
    Medical science monitor : international medical journal of experimental and clinical research, 2014, Jun-24, Volume: 20

    Topics: Adult; Alloys; Anastomosis, Surgical; Animals; Anti-Bacterial Agents; Biocompatible Materials; Cell

2014
Preparation, characterization, in vitro release and degradation of cathelicidin-BF-30-PLGA microspheres.
    PloS one, 2014, Volume: 9, Issue:6

    Topics: Antimicrobial Cationic Peptides; Apoptosis; Cathelicidins; Cell Proliferation; Cells, Cultured; Chro

2014
Poly(2-ethyl-2-oxazoline)-PLA-g-PEI amphiphilic triblock micelles for co-delivery of minicircle DNA and chemotherapeutics.
    Journal of controlled release : official journal of the Controlled Release Society, 2014, Sep-10, Volume: 189

    Topics: Animals; Antibiotics, Antineoplastic; Breast Neoplasms; Cell Line, Tumor; DNA, Circular; Doxorubicin

2014
Development of a folate-modified curcumin loaded micelle delivery system for cancer targeting.
    Colloids and surfaces. B, Biointerfaces, 2014, Sep-01, Volume: 121

    Topics: Animals; Cell Death; Cell Survival; Curcumin; Drug Delivery Systems; Endocytosis; Folic Acid; Hemoly

2014
Mitomycin C-soybean phosphatidylcholine complex-loaded self-assembled PEG-lipid-PLA hybrid nanoparticles for targeted drug delivery and dual-controlled drug release.
    Molecular pharmaceutics, 2014, Aug-04, Volume: 11, Issue:8

    Topics: Animals; Cell Line, Tumor; Cell Survival; Drug Delivery Systems; Glycine max; HeLa Cells; Hemolysis;

2014
Hemocompatibility and selective cell fate of polydopamine-assisted heparinized PEO/PLLA composite coating on biodegradable AZ31 alloy.
    Colloids and surfaces. B, Biointerfaces, 2014, Sep-01, Volume: 121

    Topics: Alloys; Blood Platelets; Cell Proliferation; Coated Materials, Biocompatible; Corrosion; Electrolysi

2014
Novel non-viral gene delivery systems composed of carbosilane dendron functionalized nanoparticles prepared from nano-emulsions as non-viral carriers for antisense oligonucleotides.
    International journal of pharmaceutics, 2015, Jan-15, Volume: 478, Issue:1

    Topics: Cell Line, Tumor; Cell Survival; Dendrimers; Emulsions; Erythrocytes; Gene Transfer Techniques; Hemo

2015
In vitro hemocompatibility studies of (poly(L-lactide) and poly(L-lactide-co-glycolide) as materials for bioresorbable stents manufacture.
    Acta of bioengineering and biomechanics, 2014, Volume: 16, Issue:4

    Topics: Absorbable Implants; Biocompatible Materials; Blood Coagulation; Blood Platelets; Erythrocyte Count;

2014
Interactions of PLGA nanoparticles with blood components: protein adsorption, coagulation, activation of the complement system and hemolysis studies.
    Nanoscale, 2015, Apr-14, Volume: 7, Issue:14

    Topics: Adsorption; Animals; Blood Coagulation; Cattle; Complement Activation; Hemolysis; Humans; Lactic Aci

2015
Plasma Free Hemoglobin Is an Independent Predictor of Mortality among Patients on Extracorporeal Membrane Oxygenation Support.
    PloS one, 2015, Volume: 10, Issue:4

    Topics: Aged; Biomarkers; Blood Transfusion; Cardiomyopathies; Extracorporeal Membrane Oxygenation; Female;

2015
Impact of poly(lactic-co-glycolic acid) nanoparticle surface charge on protein, cellular and haematological interactions.
    Colloids and surfaces. B, Biointerfaces, 2015, Dec-01, Volume: 136

    Topics: Blood Coagulation; Hemolysis; Lactic Acid; Microscopy, Electron, Scanning; Nanoparticles; Polyglycol

2015
An investigation of red blood cell concentrate quality during storage in paediatric-sized polyvinylchloride bags plasticized with alternatives to di-2-ethylhexyl phthalate (DEHP).
    Vox sanguinis, 2016, Volume: 110, Issue:3

    Topics: Adenosine Triphosphate; Blood Cell Count; Blood Gas Analysis; Blood Preservation; Diethylhexyl Phtha

2016
Attenuation of thrombosis and bacterial infection using dual function nitric oxide releasing central venous catheters in a 9day rabbit model.
    Acta biomaterialia, 2016, 10-15, Volume: 44

    Topics: Animals; Bacterial Adhesion; Bacterial Infections; Central Venous Catheters; Colony Count, Microbial

2016
Sustained Release of Antibacterial Lipopeptides from Biodegradable Polymers against Oral Pathogens.
    PloS one, 2016, Volume: 11, Issue:9

    Topics: Animals; Anti-Bacterial Agents; Biocompatible Materials; Biofilms; Castor Oil; Cell Membrane; Colori

2016
Ex vivo encapsulation of dexamethasone sodium phosphate into human autologous erythrocytes using fully automated biomedical equipment.
    International journal of pharmaceutics, 2017, Jan-30, Volume: 517, Issue:1-2

    Topics: 2,3-Diphosphoglycerate; Adenosine Triphosphate; Ataxia Telangiectasia; Automation; Case-Control Stud

2017
Storage of red blood cells in a novel polyolefin blood container: a pilot in vitro study.
    Vox sanguinis, 2017, Volume: 112, Issue:1

    Topics: 2,3-Diphosphoglycerate; Adenine; Adult; Aged; Blood Glucose; Blood Preservation; Erythrocyte Count;

2017
Critical re-appraisal of blood component quality after overnight hold of whole blood outside current room temperature limits.
    Vox sanguinis, 2017, Volume: 112, Issue:2

    Topics: 2,3-Diphosphoglycerate; Adenosine Triphosphate; Blood Platelets; Blood Preservation; Erythrocytes; H

2017
Oral administration of amphotericin B nanoparticles: antifungal activity, bioavailability and toxicity in rats.
    Drug delivery, 2017, Volume: 24, Issue:1

    Topics: Administration, Oral; Amphotericin B; Animals; Antifungal Agents; Biological Availability; Biomarker

2017
Antimicrobial activity of a new synthetic peptide loaded in polylactic acid or poly(lactic-co-glycolic) acid nanoparticles against Pseudomonas aeruginosa, Escherichia coli O157:H7 and methicillin resistant Staphylococcus aureus (MRSA).
    Nanotechnology, 2017, Mar-01, Volume: 28, Issue:13

    Topics: Amino Acid Sequence; Anti-Infective Agents; Drug Liberation; Escherichia coli O157; Hemolysis; Human

2017
Fast degrading polyesters as siRNA nano-carriers for pulmonary gene therapy.
    Journal of controlled release : official journal of the Controlled Release Society, 2008, Dec-18, Volume: 132, Issue:3

    Topics: Administration, Inhalation; Aerosols; Binding, Competitive; Cell Line; Gene Knockdown Techniques; Ge

2008
Cytotoxicity of amphotericin B-incorporated polymeric micelles composed of poly(DL-lactide-co-glycolide)/dextran graft copolymer.
    Archives of pharmacal research, 2008, Volume: 31, Issue:11

    Topics: Amphotericin B; Antifungal Agents; Candida albicans; Chemistry, Pharmaceutical; Dextrans; Drug Compo

2008
Biodegradable nanoparticles improve oral bioavailability of amphotericin B and show reduced nephrotoxicity compared to intravenous Fungizone.
    Pharmaceutical research, 2009, Volume: 26, Issue:6

    Topics: Amphotericin B; Animals; Antifungal Agents; Biological Availability; Blood Urea Nitrogen; Creatine;

2009
Fabrication and characterization of chitosan coated braided PLLA wire using aligned electrospun fibers.
    Journal of materials science. Materials in medicine, 2009, Volume: 20, Issue:11

    Topics: Animals; Biocompatible Materials; Chitosan; Electronics; Equipment Design; Erythrocytes; Hemolysis;

2009
Murine blood banking: characterization and comparisons to human blood.
    Shock (Augusta, Ga.), 2010, Volume: 34, Issue:1

    Topics: Animals; Blood Banking; Blood Preservation; Erythrocytes; Hemolysis; Humans; Lactic Acid; Male; Mice

2010
Development of amphotericin B loaded polymersomes based on (PEG)(3)-PLA co-polymers: Factors affecting size and in vitro evaluation.
    European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences, 2010, Aug-11, Volume: 40, Issue:5

    Topics: Amphotericin B; Animals; Antifungal Agents; Biological Availability; Drug Carriers; Drug Compounding

2010
Evaluation of magnesium ions release, biocorrosion, and hemocompatibility of MAO/PLLA-modified magnesium alloy WE42.
    Journal of biomedical materials research. Part B, Applied biomaterials, 2011, Volume: 96, Issue:1

    Topics: Alloys; Blood Coagulation; Coated Materials, Biocompatible; Corrosion; Dielectric Spectroscopy; Eval

2011
Preparation and characterization of thermosensitive pluronic F127-b-poly(ɛ-caprolactone) mixed micelles.
    Colloids and surfaces. B, Biointerfaces, 2011, Aug-01, Volume: 86, Issue:1

    Topics: Animals; Cattle; Cell Survival; Cells, Cultured; Doxorubicin; Drug Carriers; Hemolysis; Hep G2 Cells

2011
Clinical efficacy of a specifically targeted antimicrobial peptide mouth rinse: targeted elimination of Streptococcus mutans and prevention of demineralization.
    Caries research, 2011, Volume: 45, Issue:5

    Topics: Adolescent; Adult; Aged; Animals; Anti-Infective Agents; Antimicrobial Cationic Peptides; Bacterial

2011
Effect of thiol functionalization on the hemo-compatibility of PLGA nanoparticles.
    Journal of biomedical materials research. Part A, 2011, Dec-15, Volume: 99, Issue:4

    Topics: Adsorption; Biocompatible Materials; Cell Adhesion; Cell Line; Complement Activation; Drug Carriers;

2011
Arginase depletes plasma l-arginine and decreases pulmonary vascular reserve during experimental pulmonary embolism.
    Pulmonary pharmacology & therapeutics, 2012, Volume: 25, Issue:1

    Topics: Animals; Arginase; Arginine; Blood Pressure; Cardiac Output; Dose-Response Relationship, Drug; Enzym

2012
Interaction of curcumin nanoformulations with human plasma proteins and erythrocytes.
    International journal of nanomedicine, 2011, Volume: 6

    Topics: Analysis of Variance; Blood Proteins; Cell Line, Tumor; Curcumin; Drug Carriers; Erythrocytes; Hemol

2011
Galactose decorated PLGA nanoparticles for hepatic delivery of acyclovir.
    Drug development and industrial pharmacy, 2013, Volume: 39, Issue:12

    Topics: Acyclovir; Animals; Antiviral Agents; Chemistry, Pharmaceutical; Delayed-Action Preparations; Drug C

2013
Preparation and characterization of monensin loaded PLGA nanoparticles: in vitro anti-malarial activity against Plasmodium falciparum.
    Journal of biomedical nanotechnology, 2012, Volume: 8, Issue:1

    Topics: Antimalarials; Calorimetry, Differential Scanning; Cells, Cultured; Emulsions; Erythrocytes; Hemolys

2012
Preparation of biocompatible chitosan grafted poly(lactic acid) nanoparticles.
    International journal of biological macromolecules, 2012, Volume: 51, Issue:3

    Topics: Biocompatible Materials; Cell Line; Chitosan; Hemolysis; Humans; Lactic Acid; Nanoparticles; Polyest

2012
Enhanced endothelialization of a new stent polymer through surface enhancement and incorporation of growth factor-delivering microparticles.
    Journal of cardiovascular translational research, 2012, Volume: 5, Issue:4

    Topics: Antibodies; Antigens, CD34; Blood Coagulation; Blood Platelets; Cell Adhesion; Cell Proliferation; C

2012
PLGA nanoparticles and nanosuspensions with amphotericin B: Potent in vitro and in vivo alternatives to Fungizone and AmBisome.
    Journal of controlled release : official journal of the Controlled Release Society, 2012, Aug-10, Volume: 161, Issue:3

    Topics: Amphotericin B; Animals; Antifungal Agents; Aspergillosis; Cell Line; Colony Count, Microbial; Eryth

2012
Tanshinone IIA stimulates erythrocyte phosphatidylserine exposure.
    Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology, 2012, Volume: 30, Issue:1

    Topics: Abietanes; Adenosine Triphosphate; Calcium; Cell Death; Cell Size; Ceramides; Erythrocyte Membrane;

2012
A poly(γ, L-glutamic acid)-citric acid based nanoconjugate for cisplatin delivery.
    Biomaterials, 2012, Volume: 33, Issue:29

    Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Chromatography; Cisplatin; Citric Acid; Drug Deliv

2012
Improved antifungal activity of itraconazole-loaded PEG/PLA nanoparticles.
    Journal of microencapsulation, 2013, Volume: 30, Issue:3

    Topics: Antifungal Agents; Calorimetry, Differential Scanning; Hemolysis; Itraconazole; Lactic Acid; Nanopar

2013
A novel monomethoxy polyethylene glycol-polylactic acid polymeric micelles with higher loading capacity for docetaxel and well-reconstitution characteristics and its anti-metastasis study.
    Chemical & pharmaceutical bulletin, 2012, Volume: 60, Issue:9

    Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Survival; Docetaxel; Drug Carriers; Guinea Pi

2012
The 30 minute rule for red blood cells: in vitro quality assessment after repeated exposure to 30°C.
    Transfusion, 2013, Volume: 53, Issue:6

    Topics: 2,3-Diphosphoglycerate; Adenosine Triphosphate; Blood Banks; Blood Preservation; Blood Specimen Coll

2013
Combination of LC-MS- and GC-MS-based metabolomics to study the effect of ozonated autohemotherapy on human blood.
    Journal of proteome research, 2012, Dec-07, Volume: 11, Issue:12

    Topics: Adult; Antioxidants; Biomarkers; Blood Cell Count; Chromatography, Liquid; Gas Chromatography-Mass S

2012
Bacteriocin production, antibiotic susceptibility and prevalence of haemolytic and gelatinase activity in faecal lactic acid bacteria isolated from healthy Ethiopian infants.
    Microbial ecology, 2013, Volume: 65, Issue:2

    Topics: Bacteriocins; Cytotoxins; DNA, Bacterial; Drug Resistance, Bacterial; Enterococcus; Ethiopia; Feces;

2013
Testing of extracorporeal membrane oxygenation circuit related hemolysis using long-term stored packed red cells and fresh frozen plasma.
    Artificial organs, 2004, Volume: 28, Issue:5

    Topics: Blood Glucose; Erythrocyte Transfusion; Erythrocytes; Extracorporeal Membrane Oxygenation; Hemoglobi

2004
Bacteriostatic properties of biomatrices against common orthopaedic pathogens.
    Biochemical and biophysical research communications, 2004, Aug-20, Volume: 321, Issue:2

    Topics: Anti-Bacterial Agents; Bacteria; Biocompatible Materials; Cell Division; Collagen; Hemolysis; Hyalur

2004
Interaction of PLGA nanoparticles with human blood constituents.
    Colloids and surfaces. B, Biointerfaces, 2005, Feb-10, Volume: 40, Issue:2

    Topics: Blood; Blood Chemical Analysis; Blood Coagulation; Drug Carriers; Electrolytes; Hemolysis; Humans; H

2005
A mixed polymeric micellar formulation of itraconazole: Characteristics, toxicity and pharmacokinetics.
    Journal of controlled release : official journal of the Controlled Release Society, 2007, Jan-22, Volume: 117, Issue:1

    Topics: Animals; Antifungal Agents; Area Under Curve; Chemical Phenomena; Chemistry, Pharmaceutical; Chemist

2007
In vitro quality of red blood cells (RBCs) collected by multicomponent apheresis compared to manually collected RBCs during 49 days of storage.
    Transfusion, 2007, Volume: 47, Issue:4

    Topics: Adenosine Triphosphate; Adult; Blood Component Removal; Blood Preservation; Blood Specimen Collectio

2007
Storage of equine red blood cells as a concentrate.
    Veterinary journal (London, England : 1997), 2008, Volume: 176, Issue:2

    Topics: 2,3-Diphosphoglycerate; Adenosine Triphosphate; Animals; Blood Preservation; Erythrocytes; Hemolysis

2008
Effect of bee venom peptide-copolymer interactions on thermosensitive hydrogel delivery systems.
    International journal of pharmaceutics, 2007, Dec-10, Volume: 345, Issue:1-2

    Topics: Algorithms; Bee Venoms; Drug Delivery Systems; Excipients; Hemolysis; Humans; Hydrogels; In Vitro Te

2007
Biocompatibility of poly(D,L-lactide-co-glycolide) nanoparticles conjugated with alendronate.
    Biomaterials, 2008, Volume: 29, Issue:10

    Topics: Alendronate; Alkaline Phosphatase; Cell Survival; Hemolysis; Humans; Lactic Acid; Leukocyte Count; M

2008
General and transport properties of hypotonic and isotonic preparations of resealed erythrocyte ghosts.
    The Journal of membrane biology, 1981, Volume: 63, Issue:1-2

    Topics: Ammonium Chloride; Arabinose; Cell Membrane Permeability; Erythritol; Erythrocyte Membrane; Erythroc

1981
Effects of 3-5 log10 pre-storage leucocyte depletion on red cell storage and metabolism.
    British journal of haematology, 1994, Volume: 87, Issue:2

    Topics: Adenosine Triphosphate; Blood Glucose; Blood Preservation; Cell Separation; Erythrocytes; Filtration

1994
Half-strength citrate CPD combined with a new additive solution for improved storage of red blood cells suitable for clinical use.
    Vox sanguinis, 1993, Volume: 65, Issue:4

    Topics: 2,3-Diphosphoglycerate; Blood Donors; Blood Preservation; Citrates; Diphosphoglyceric Acids; Erythro

1993
Effect of lactic acid on water content and osmotic fragility of erythrocytes in vivo.
    The Journal of sports medicine and physical fitness, 1997, Volume: 37, Issue:1

    Topics: Animals; Body Water; Centrifugation; Chromatography, Gas; Erythrocyte Membrane; Erythrocytes; Hemoly

1997
Effect of 6-hour exposure to 20 degrees C on the ATP content and other biochemical measures of CPDA-1 packed red cells.
    Clinical laboratory, 2000, Volume: 46, Issue:5-6

    Topics: Adenine; Adenosine Triphosphate; Anticoagulants; Blood Glucose; Blood Preservation; Citrates; Cryopr

2000
L-sorbose does not cause hemolysis in dog erythrocytes with inherited high Na, K-ATPase activity.
    Comparative biochemistry and physiology. C, Comparative pharmacology and toxicology, 1992, Volume: 101, Issue:3

    Topics: Adenosine Triphosphate; Animals; Dogs; Erythrocytes; Hemolysis; Humans; Lactates; Lactic Acid; Male;

1992
Improving lactate analysis with the YSI 2300 GL: hemolyzing blood samples makes results comparable with those for deproteinized whole blood.
    Clinical chemistry, 1992, Volume: 38, Issue:10

    Topics: Biosensing Techniques; Blood Chemical Analysis; Drug Stability; Hemolysis; Humans; Indicators and Re

1992
Storage of saline-adenine-glucose-mannitol-suspended red cells in a new plastic container: polyvinylchloride plasticized with butyryl-n-trihexyl-citrate.
    Transfusion, 1991, Volume: 31, Issue:1

    Topics: 2,3-Diphosphoglycerate; Adenine; Adenine Nucleotides; Adenosine Triphosphate; Blood Glucose; Blood P

1991
[Viability of human red blood cells preserved for 35 days after leukocyte depletion (in vitro study)].
    Revue francaise de transfusion et d'hemobiologie : bulletin de la Societe nationale de transfusion sanguine, 1989, Volume: 32, Issue:1

    Topics: 2,3-Diphosphoglycerate; Adenosine Triphosphate; Blood Component Removal; Blood Glucose; Blood Preser

1989
[Hemoglobin aggregation in erythrocytes as a factor in the disturbance of their structural and functional integrity].
    Gematologiia i transfuziologiia, 1987, Volume: 32, Issue:10

    Topics: Animals; Erythrocyte Aggregation; Erythrocytes; Hemoglobins; Hemolysis; Hot Temperature; Lactates; L

1987
[The effect of rewarming of stored blood on plasma value and erythrocytes].
    Der Anaesthesist, 1985, Volume: 34, Issue:7

    Topics: Blood Cell Count; Blood Preservation; Blood Viscosity; Cholesterol; Erythrocyte Count; Hemoglobins;

1985